Jeon et al. demonstrated that luteolin combined with celecoxib synergistically suppressed tumor growth in multiple breast cancer cell lines, mediated through Akt inhibition and cell-line–specific modulation of ERK signaling [103]. The gene discussed is AKT1; the disease is breast carcinoma.